Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
I-MAB names Ivan Yifei Zhu as Chief Commercial Officer » 08:02
07/28/20
07/28
08:02
07/28/20
08:02
IMAB

I-MAB

$30.00 /

+1.5 (+5.26%)

I-Mab announced the…

I-Mab announced the appointment of Ivan Yifei Zhu as its Chief Commercial Officer, effective August 10. Zhu will report directly to Dr. Jingwu Zang, Founder, Honorary Chairman and Director of I-Mab. In this role, Zhu will focus on building and developing I-Mab's commercialization infrastructure and strategies, and preparing the company for upcoming product launches. Prior to joining I-Mab, Zhu served as Vice President and General Manager of the sales division of Qilu Pharmaceutical Group.

ShowHide Related Items >><<
IMAB I-MAB
$30.00 /

+1.5 (+5.26%)

IMAB I-MAB
$30.00 /

+1.5 (+5.26%)

07/27/20 Cantor Fitzgerald
I-MAB initiated with an Overweight at Cantor Fitzgerald
02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
IMAB I-MAB
$30.00 /

+1.5 (+5.26%)

  • 17
    Jan
IMAB I-MAB
$30.00 /

+1.5 (+5.26%)

Over a week ago
Initiation
I-MAB initiated with an Overweight at Cantor Fitzgerald » 06:29
07/27/20
07/27
06:29
07/27/20
06:29
IMAB

I-MAB

$28.50 /

-1.3 (-4.36%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen initiated coverage of I-MAB with an Overweight rating and $50 price target. Chen says I-MAB is unique among China-based biotech companies because it exclusively focuses on the discovery, development and commercialization of first-in-class/best-in-class drugs. The analyst believes the pace of innovation and the market potential for new drugs in China is overlooked and that TJC4, TJD5 and TJM2 are best-in-class global opportunities for I-MAB.

ShowHide Related Items >><<
IMAB I-MAB
$28.50 /

-1.3 (-4.36%)

IMAB I-MAB
$28.50 /

-1.3 (-4.36%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
IMAB I-MAB
$28.50 /

-1.3 (-4.36%)

  • 17
    Jan
IMAB I-MAB
$28.50 /

-1.3 (-4.36%)

Hot Stocks
I-MAB announces $20M stock repurchase program » 16:16
07/15/20
07/15
16:16
07/15/20
16:16
IMAB

I-MAB

$32.64 /

+2.335 (+7.70%)

I-Mab announced that its…

I-Mab announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $20M of its ordinary shares in the form of American depositary shares.

ShowHide Related Items >><<
IMAB I-MAB
$32.64 /

+2.335 (+7.70%)

IMAB I-MAB
$32.64 /

+2.335 (+7.70%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
IMAB I-MAB
$32.64 /

+2.335 (+7.70%)

  • 17
    Jan
IMAB I-MAB
$32.64 /

+2.335 (+7.70%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 19:08
05/27/20
05/27
19:08
05/27/20
19:08
NTNX

Nutanix

$24.94 /

+0.53 (+2.17%)

, COHR

Coherent

$149.11 /

+3.8 (+2.62%)

, HPQ

HP Inc.

$17.13 /

+0.06 (+0.35%)

, NTAP

NetApp

$46.30 /

+1.23 (+2.73%)

, ADSK

Autodesk

$199.71 /

+0.28 (+0.14%)

, HTZ

Hertz

$1.31 /

+0.7199 (+122.00%)

, IOVA

Iovance Biotherapeutics

$38.12 /

+0.66 (+1.76%)

, ARNA

Arena Pharmaceuticals

$58.07 /

+1.16 (+2.04%)

, CRNC

Cerence

$33.05 /

+0.47 (+1.44%)

, BCRX

BioCryst

$5.03 /

-0.17 (-3.27%)

, IMMU

Immunomedics

$34.18 /

+0.1 (+0.29%)

, PEN

Penumbra

$170.74 /

+1.29 (+0.76%)

, TWTR

Twitter

$33.06 /

-0.96 (-2.82%)

, PLT

Plantronics

$14.66 /

+0.67 (+4.79%)

, IMAB

I-MAB

$23.87 /

+0.665 (+2.87%)

, BA

Boeing

$149.46 /

+4.77 (+3.30%)

, HPP

Hudson Pacific

$24.18 /

+1.06 (+4.59%)

, DHC

Diversified Healthcare Trust

$3.23 /

+0.03 (+0.94%)

, PLMR

Palomar

$65.68 /

+2.57 (+4.07%)

, PHAS

PhaseBio

$4.42 /

-0.03 (-0.67%)

, SPTN

SpartanNash

$20.57 /

-0.02 (-0.10%)

, WDAY

Workday

$170.10 /

+1.72 (+1.02%)

, TOL

Toll Brothers

$32.95 /

+2.835 (+9.42%)

, BGFV

Big 5 Sporting

$1.94 /

+0.06 (+3.19%)

, SMTC

Semtech

$50.13 /

+1.18 (+2.41%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

COHR Coherent
$149.11 /

+3.8 (+2.62%)

BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

05/21/20 JPMorgan
Nutanix price target lowered to $24 from $27 at JPMorgan
05/19/20 OTR Global
Nutanix downgraded to Mixed from Positive at OTR Global
04/27/20 Needham
Nutanix price target lowered to $24 from $42 at Needham
04/23/20 Cleveland Research
Nutanix trends in April softened versus prior months, says Cleveland Research
COHR Coherent
$149.11 /

+3.8 (+2.62%)

04/23/20 Goldman Sachs
Coherent upgraded to Buy from Neutral at Goldman Sachs
02/10/20
Fly Intel: Top five analyst initiations
02/10/20 Stifel
Coherent transferred with a Buy, $178 price target at Stifel
02/06/20 Piper Sandler
Coherent price target lowered to $195 from $205 at Piper Sandler
HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

05/26/20 Credit Suisse
HP Inc. price target lowered to $17 from $22 at Credit Suisse
05/22/20 JPMorgan
HP shares worth owning through downturn, says JPMorgan
04/27/20 Loop Capital
Xerox, Park City, NetApp, HP Enterprise cut to Hold from Buy at Loop Capital
04/21/20 Deutsche Bank
HP Inc. price target lowered to $17 from $20 at Deutsche Bank
NTAP NetApp
$46.30 /

+1.23 (+2.73%)

05/19/20 Barclays
Barclays lowers estimates in IT hardware after April survey
05/11/20
Fly Intel: Top five analyst downgrades
05/11/20 Stifel
NetApp downgraded to Hold from Buy at Stifel
ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

05/22/20 Deutsche Bank
Autodesk price target lowered to $215 from $230 at Deutsche Bank
05/21/20 Citi
Citi sees difficult setup for Autodesk into results, cuts price target
05/19/20 KeyBanc
Autodesk price target raised to $210 from $200 at KeyBanc
05/07/20 OTR Global
Autodesk downgraded to Mixed from Positive at OTR Global
HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

04/29/20 Oppenheimer
Iovance Biotherapeutics price target raised to $43 from $35 at Oppenheimer
04/29/20 H.C. Wainwright
Iovance Biotherapeutics price target raised to $48 from $36 at H.C. Wainwright
04/27/20 Piper Sandler
AACR abstract for Moffitt study positive for Iovance, says Piper Sandler
04/22/20 Piper Sandler
AACR meeting should bring more support for Iovance TILs, says Piper Sandler
ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
CRNC Cerence
$33.05 /

+0.47 (+1.44%)

05/27/20 Wedbush
Cerence price target raised to $40 from $27 at Wedbush
05/26/20 Raymond James
Cerence downgraded to Outperform from Strong Buy at Raymond James
05/26/20 Raymond James
Cerence downgraded to Outperform from Strong Buy at Raymond James
05/12/20
Fly Intel: Top five analyst initiations
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
04/24/20
Fly Intel: Top five analyst upgrades
PEN Penumbra
$170.74 /

+1.29 (+0.76%)

05/08/20 Citi
Penumbra price target raised to $214 from $192 at Citi
03/04/20 Citi
Penumbra initiated with a Buy at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/26/20 Canaccord
Penumbra weakness buying opportunity, says Canaccord
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
05/01/20
Fly Intel: Top five analyst downgrades
05/01/20 Deutsche Bank
Twitter price target raised to $28 from $22 at Deutsche Bank
PLT Plantronics
$14.66 /

+0.67 (+4.79%)

04/16/20 Morgan Stanley
Morgan Stanley cuts Plantronics to Underweight citing upcoming challenges
04/16/20 Morgan Stanley
Plantronics downgraded to Underweight from Equal Weight at Morgan Stanley
03/30/20 JPMorgan
Plantronics downgraded to Underweight from Neutral at JPMorgan
03/30/20 JPMorgan
Plantronics downgraded to Underweight from Neutral at JPMorgan
IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
BA Boeing
$149.46 /

+4.77 (+3.30%)

05/22/20 Canaccord
Boeing price target lowered to $155 from $175 at Canaccord
05/20/20 RBC Capital
RBC starts Boeing at Outperform on favorable risk/reward profile
05/20/20 RBC Capital
Boeing initiated with an Outperform at RBC Capital
05/05/20 Nord/LB
Boeing downgraded to Sell from Hold at Nord/LB
HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

04/16/20 Jefferies
Hudson Pacific initiated with a Hold at Jefferies
02/04/20 Mizuho
Hudson Pacific assumed with a Buy at Mizuho
01/15/20 Mizuho
Hudson Pacific upgraded to Buy from Neutral at Mizuho
11/08/19 Goldman Sachs
Hudson Pacific initiated with a Buy at Goldman Sachs
DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

05/19/20 RBC Capital
Diversified Healthcare Trust price target lowered to $3 from $7 at RBC Capital
03/11/20 Mizuho
Sabra Health Care to be pressured by coronavirus at facility, says Mizuho
01/16/20 Wells Fargo
Diversified Healthcare Trust cut to Equal Weight from Overweight at Wells Fargo
01/07/20 Raymond James
Healthcare REIT sector downgraded to Market Weight at Raymond James
PLMR Palomar
$65.68 /

+2.57 (+4.07%)

01/14/20 JMP Securities
Palomar price target raised to $55 from $50 at JMP Securities
01/10/20 Keefe Bruyette
Palomar target raised to $58 after share offering at Keefe Bruyette
12/16/19 William Blair
Palomar should be bought despite recent rally, says William Blair
12/08/19 Keefe Bruyette
Palomar price target raised to $57 from $48 at Keefe Bruyette
PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

05/07/20 Stifel
Portola deal highlights value of PhaseBio's PB2452, says Stifel
04/06/20 Citi
PhaseBio price target lowered to $11 from $25 at Citi
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/16/20 Stifel
PhaseBio acquisition of PB6440 an 'excellent' strategic move, says Stifel
SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

03/19/20 Barclays
SpartanNash upgraded to Equal Weight from Underweight at Barclays
03/18/20 BMO Capital
SpartanNash upgraded to Market Perform from Underperform at BMO Capital
10/04/19
SpartanNash management to meet with Loop Capital
WDAY Workday
$170.10 /

+1.72 (+1.02%)

05/21/20 OTR Global
Workday downgraded to Mixed from Positive at OTR Global
05/18/20
Fly Intel: Top five analyst downgrades
05/18/20 Cleveland Research
Workday downgraded to Neutral from Buy at Cleveland Research
05/18/20 RBC Capital
Workday price target lowered to $194 from $230 at RBC Capital
TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

05/27/20 Credit Suisse
Toll Brothers initiated with a Neutral at Credit Suisse
05/27/20 Credit Suisse
KB Home initiated with an Outperform at Credit Suisse
05/11/20 Wedbush
Toll Brothers price target lowered to $35 from $48 at Wedbush
05/04/20 Evercore ISI
Toll Brothers upgraded to In Line from Underperform at Evercore ISI
BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

03/12/20 Susquehanna
Semtech results inline and guidance better than feared, says Susquehanna
03/12/20 Loop Capital
Semtech price target lowered to $46 from $56 at Loop Capital
03/12/20 B. Riley FBR
Semtech price target lowered to $50 from $55 at B. Riley FBR
03/12/20 Needham
Semtech upgraded to Buy from Hold at Needham
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

COHR Coherent
$149.11 /

+3.8 (+2.62%)

BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

  • 29
    May
  • 28
    May
  • 28
    May
  • 28
    May
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

Hot Stocks
I-MAB reports Part 1 interim results from study for antibody for CRS » 16:18
05/27/20
05/27
16:18
05/27/20
16:18
IMAB

I-MAB

$23.94 /

+0.735 (+3.17%)

I-Mab announced interim…

I-Mab announced interim results from a multi-center, double blinded, randomized, placebo-controlled, three-arm clinical study of TJM2 in patients with cytokine release syndrome, or CRS, associated with severe COVID-19. TJM2, also known as TJ003234, is an I-Mab-discovered neutralizing antibody against human granulocyte-macrophage colony stimulating factor, or GM-CSF, an important cytokine that plays a critical role in acute and chronic tissue inflammation. Part 1 of the study evaluated the safety and tolerability of TJM2 in a total of 24 patients. The DMC concluded that I-Mab can commence the Part 2 of the study as planned, indicating TJM2 is safe and well-tolerated in the severe COVID-19 patients in the study. The DMC also endorsed protocol changes, including broadening the inclusion criteria and dosing all patients at 6 mg/kg of TJM2 or placebo. Part 2 of the study with a similar design to Part 1 will target the same patient population and is expected to be initiated shortly. It will evaluate the efficacy, safety and cytokine levels following a single dose of 6mg/kg TJM2 or placebo in 120 patients with severe COVID-19. Recently published data indicate that COVID-19 can induce a cytokine storm instigated by extensive immune cell infiltration and the release of GM-CSF and IL-6.

ShowHide Related Items >><<
IMAB I-MAB
$23.94 /

+0.735 (+3.17%)

IMAB I-MAB
$23.94 /

+0.735 (+3.17%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
IMAB I-MAB
$23.94 /

+0.735 (+3.17%)

IMAB I-MAB
$23.94 /

+0.735 (+3.17%)

Hot Stocks
I-MAB cleared for Phase 2 trial of glioblastoma multiforme candidate in China » 08:03
05/21/20
05/21
08:03
05/21/20
08:03
IMAB

I-MAB

$22.22 /

-4.95 (-18.22%)

I-Mab and Genexine, a…

I-Mab and Genexine, a clinical-stage biotechnology company focused on developing innovative immunotherapeutics and novel long-acting biologics, announced that the China National Medical Products Administration has cleared the initiation of a Phase 2 clinical trial of TJ107/HyLeukin-7, the novel long-acting recombinant human interleukin-7 in lymphopenic patients with newly-diagnosed glioblastoma multiforme. In addition, the two companies expanded their collaboration beyond the initial agreement to include development of TJ107/HyLeukin-7 for this indication. The affirmation was provided by NMPA in response to a pre-IND request to support the clinical development plans for TJ107/HyLeukin-7 as a potential treatment for GBM. Per the clearance, I-Mab and Genexine are able to initiate a phase 2 clinical study in China without additional IND application submission required. I-Mab will be mainly responsible for conducting the Phase 2 GBM clinical trial in China, and Genexine will share the development strategies, data and costs for success of this clinical trial. Financial terms are not disclosed.

ShowHide Related Items >><<
IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

Conference/Events
Citigroup to hold a virtual conference » 04:55
05/21/20
05/21
04:55
05/21/20
04:55
IMAB

I-MAB

$22.22 /

-4.95 (-18.22%)

, HCM

Hutchison China MediTech

$22.21 /

-0.32 (-1.42%)

, LFC

China Life Insurance

$9.86 /

+0.01 (+0.10%)

, RUHN

Ruhnn

$2.78 /

-0.22 (-7.33%)

, XNET

Xunlei

$3.55 /

+0.09 (+2.60%)

Pan-Asia Regional…

Pan-Asia Regional Investor Virtual Conference will be held on May 19-21.

ShowHide Related Items >><<
XNET Xunlei
$3.55 /

+0.09 (+2.60%)

IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

HCM Hutchison China MediTech
$22.21 /

-0.32 (-1.42%)

IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
HCM Hutchison China MediTech
$22.21 /

-0.32 (-1.42%)

03/13/20
Fly Intel: Top analyst initiations
03/12/20 Cantor Fitzgerald
Hutchison China MediTech initiated with an Overweight at Cantor Fitzgerald
02/20/20
Fly Intel: Top five analyst initiations
02/20/20 Goldman Sachs
Hutchison China MediTech initiated with a Buy at Goldman Sachs
LFC China Life Insurance
$9.86 /

+0.01 (+0.10%)

03/16/20 CLSA
China Life Insurance upgraded to Buy at CLSA with sector at 'life low'
03/16/20 CLSA
China Life Insurance upgraded to Buy from Outperform at CLSA
01/06/20 CLSA
China Life Insurance upgraded to Outperform from Underperform at CLSA
10/30/19 CIMB
China Life Insurance upgraded to Hold from Reduce at CIMB
RUHN Ruhnn
$2.78 /

-0.22 (-7.33%)

XNET Xunlei
$3.55 /

+0.09 (+2.60%)

IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

IMAB I-MAB
$22.22 /

-4.95 (-18.22%)

XNET Xunlei
$3.55 /

+0.09 (+2.60%)

Conference/Events
Citigroup to hold a virtual conference » 08:19
05/20/20
05/20
08:19
05/20/20
08:19
IMAB

I-MAB

$27.17 /

+6.67 (+32.54%)

, HCM

Hutchison China MediTech

$22.53 /

+0.37 (+1.67%)

, LFC

China Life Insurance

$9.85 /

+0.03 (+0.31%)

, RUHN

Ruhnn

$3.00 /

-0.05 (-1.64%)

, XNET

Xunlei

$3.46 /

+0.02 (+0.58%)

Pan-Asia Regional…

Pan-Asia Regional Investor Virtual Conference will be held on May 19-21.

ShowHide Related Items >><<
XNET Xunlei
$3.46 /

+0.02 (+0.58%)

IMAB I-MAB
$27.17 /

+6.67 (+32.54%)

HCM Hutchison China MediTech
$22.53 /

+0.37 (+1.67%)

IMAB I-MAB
$27.17 /

+6.67 (+32.54%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
HCM Hutchison China MediTech
$22.53 /

+0.37 (+1.67%)

03/13/20
Fly Intel: Top analyst initiations
03/12/20 Cantor Fitzgerald
Hutchison China MediTech initiated with an Overweight at Cantor Fitzgerald
02/20/20
Fly Intel: Top five analyst initiations
02/20/20 Goldman Sachs
Hutchison China MediTech initiated with a Buy at Goldman Sachs
LFC China Life Insurance
$9.85 /

+0.03 (+0.31%)

03/16/20 CLSA
China Life Insurance upgraded to Buy at CLSA with sector at 'life low'
03/16/20 CLSA
China Life Insurance upgraded to Buy from Outperform at CLSA
01/06/20 CLSA
China Life Insurance upgraded to Outperform from Underperform at CLSA
10/30/19 CIMB
China Life Insurance upgraded to Hold from Reduce at CIMB
RUHN Ruhnn
$3.00 /

-0.05 (-1.64%)

XNET Xunlei
$3.46 /

+0.02 (+0.58%)

IMAB I-MAB
$27.17 /

+6.67 (+32.54%)

IMAB I-MAB
$27.17 /

+6.67 (+32.54%)

XNET Xunlei
$3.46 /

+0.02 (+0.58%)

Hot Stocks
I-MAB says first patient dosed in Phase 1/2 clinical study of CD73 antibody TJD5 » 08:03
05/13/20
05/13
08:03
05/13/20
08:03
IMAB

I-MAB

$18.17 /

+0.54 (+3.06%)

I-Mab announced that the…

I-Mab announced that the first patient has been dosed in a Phase 1/2 clinical study in China to evaluate I-Mab's proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors.

ShowHide Related Items >><<
IMAB I-MAB
$18.17 /

+0.54 (+3.06%)

IMAB I-MAB
$18.17 /

+0.54 (+3.06%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
IMAB I-MAB
$18.17 /

+0.54 (+3.06%)

IMAB I-MAB
$18.17 /

+0.54 (+3.06%)

Over a quarter ago
Hot Stocks
MorphoSys, I-MAB announce 1st patient dosed in multiple myeloma study in China » 16:43
04/27/20
04/27
16:43
04/27/20
16:43
MOR

MorphoSys

$25.75 /

+1.27 (+5.19%)

, IMAB

I-MAB

$15.69 /

+1.64 (+11.67%)

I-Mab (IMAB) and…

I-Mab (IMAB) and MorphoSys (MOR) jointly announced that the first patient has been dosed in a phase 3 clinical study in mainland China to evaluate MorphoSys' investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (r/r MM). Under a licensing agreement with MorphoSys, I-Mab has exclusive rights for development and commercialization of TJ202/MOR202 in mainland China, Taiwan, Hong Kong and Macao.The clinical trial in mainland China is a randomized, open-label, parallel-controlled, multi-center study to evaluate the efficacy and safety of the combination of TJ202/MOR202, lenalidomide and dexamethasone versus the combination of lenalidomide and dexamethasone in patients with r/r MM who received at least one prior line of treatment. This multi-center study has already started at sites in Taiwan in April 2019 and now officially started in mainland China as part of the coordinated effort to accelerate the study. "TJ202/MOR202 is a front-runner candidate that adequately demonstrates our fast-to-market development strategy, representing a highly differentiated clinical development approach to provide new treatment options for unmet medical needs," said Dr. Joan Shen, CEO of I-Mab. "The phase 3 study is the second registrational trial of TJ202 as a potential second line treatment option for patients with multiple myeloma in Greater China." "We are delighted that our partner I-Mab has dosed the first patient in the ongoing phase 3 study for TJ202/MOR202 in mainland China, which marks an important step in the development of this compound," commented Dr. Malte Peters, Chief Research & Development Officer of MorphoSys. "There is a high need for the treatment of patients with r/r multiple myeloma in the Greater China area and we look forward to the further development of TJ202/MOR202 by our partner I-Mab in this indication."

ShowHide Related Items >><<
MOR MorphoSys
$25.75 /

+1.27 (+5.19%)

03/25/20 Oppenheimer
Incyte price target lowered to $85 from $99 at Oppenheimer
03/11/20 Credit Suisse
Incyte price target lowered to $81 from $86 at Credit Suisse
01/14/20 JMP Securities
Incyte price target raised to $121 from $99 at JMP Securities
01/13/20 Piper Sandler
Piper says terms of Incyte deal 'attractive' for Morphosys
IMAB I-MAB
$15.69 /

+1.64 (+11.67%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.